Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib eye drops in neovascular AMD
NCT00612456Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2008
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of pazopanib in neovascular age-related macular degeneration (NVAMD), sponsored by GSK. Started Mar 2008; status: completed.
02
Drugs
pazopanib
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00612456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00612456.